Rectify Pharmaceuticals lands $100m Series A

Rectify Pharmaceuticals Inc, a biotechnology company, has secured $100 million in Series A financing.

Rectify Pharmaceuticals Inc, a biotechnology company, has secured $100 million in Series A financing. Atlas Venture, Omega Funds, Forbion, and Longwood Fund led the round.

Source: Press Release